Archive
2024
- The CentiMarker Project: Standardizing Quantitative Alzheimer’s disease Fluid Biomarkers for Biologic Interpretation
- Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment
- MRI Signature of α-Synuclein Pathology in Asymptomatic Stages and a Memory Clinic Population
- Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
- Harmonizing tau positron emission tomography in Alzheimer’s disease: The CenTauR scale and the joint propagation model
- A clinical perspective on the revised criteria for diagnosis and staging of Alzheimer’s disease
- Clinical recognition of frontotemporal dementia with right anterior temporal predominance: A multicenter retrospective cohort study
- Divergent functional connectivity changes associated with white matter hyperintensities
- Continuous β-Amyloid CSF/PET Imbalance Model to Capture Alzheimer Disease Heterogeneity
- Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
- A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings
- A Comprehensive Head-to-Head Comparison of Key Plasma Phosphorylated Tau 217 Biomarker Tests
- Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns
- Acceptable performance of blood biomarker tests of amyloid pathology – recommendations from the Global CEO Initiative on Alzheimer’s Disease
- Revised criteria for the diagnosis and staging of Alzheimer’s disease
- Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup
- Associations of modifiable and non-modifiable risk factors with cognitive functions – a prospective, population-based, 17 years follow-up study of 3,229 individuals
- Effects of time of the day at sampling on CSF and plasma levels of Alzheimer’ disease biomarkers
- In vivo detection of Alzheimer’s and Lewy body disease concurrence: Clinical implications and future perspectives
- Structural and functional connectivity associations with anterior cingulate sulcal variability
- Head-to-Head Comparison of Tau and Amyloid Positron Emission Tomography Visual Reads for Differential Diagnosis of Neurodegenerative Disorders: An International, Multicenter Study
- MRI-Derived AD Signature of Cortical Thinning and Plasma P-Tau217 for Predicting Alzheimer Dementia Among Community-Dwelling Older Adults
- Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α-synuclein pathology
- Prediction of future cognitive decline among cognitively unimpaired individuals using measures of soluble phosphorylated tau or tau tangle pathology
- Remote and unsupervised digital memory assessments can reliably detect cognitive impairment in Alzheimer’s disease
- Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment
- Identification of distinct and shared biomarker panels in different manifestations of cerebral small vessel disease through proteomic profiling
- A machine learning-based prediction of tau load and distribution in Alzheimer’s disease using plasma, MRI and clinical variables
- Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly
- Medial temporal lobe atrophy patterns in early- versus late-onset amnestic Alzheimer’s disease
- Disease staging of Alzheimer’s disease using a CSF-based biomarker model
- Plasma p-tau217 in Alzheimer’s disease: Lumipulse and ALZpath SIMOA head-to-head comparison
- Fixel-Based Analysis Reveals Tau-Related White Matter Changes in Early Stages of Alzheimer’s Disease
- Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases
- Biomarker-based staging of Alzheimer disease: rationale and clinical applications
- Associations between structural brain changes and blood neurofilament light chain protein in treatment-resistant schizophrenia
- Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration.
- Altered empathy processing in frontotemporal dementia A task-based fMRI study
- Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms
- Is GBA1 T369M not a risk factor for Parkinson’s disease in the Swedish population?
- A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings
- Diffusion MRI tracks cortical microstructural changes during the early stages of Alzheimer’s disease.
- Interactions between vascular burden and amyloid-β pathology on trajectories of tau accumulation.
- Highly Accurate Blood Test for Alzheimer’s Disease Comparable or Superior to Clinical CSF Tests.
- Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease.
- Prognostic and Predictive Factors in Early Alzheimer’s Disease: A Systematic Review.
- Putaminal T1/T2-weighted ratio is increased in PSP compared to PD and healthy controls, a multi-cohort study.
- The Relationship between p-tau217, p-tau231, and p-tau205 in the Human Brain Is Affected by the Cellular Environment and Alzheimer’s Disease Pathology.
- Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis.
- Effects of certain pre-analytical factors on the performance of plasma phospho-tau217.
- Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer Disease.
- Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases.
- Diffusion weighted magnetic resonance spectroscopy revealed neuronal specific microstructural alterations in Alzheimer’s disease.
- Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology.
- The fluorescent ligand bTVBT2 reveals increased p-tau uptake by retinal microglia in Alzheimer’s disease patients and AppNL-F/NL-F mice.
- Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies.
2023
2022
2021
- Structural and functional neuroimaging changes associated with cognitive impairment and dementia in Parkinson’s disease.
- Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures
- Association of CSF Aβ38 Levels With Risk of Alzheimer Disease-Related Decline.
- Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
- Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques.
- The protective gene dose effect of the APOE ε2 allele on gray matter volume in cognitively unimpaired individuals.
- Characterization of pre-analytical sample handling effects on a panel of Alzheimer’s disease-related blood-based biomarkers: Results from the Standardization of Alzheimer’s Blood Biomarkers (SABB) working group.
- Connecting Cohorts to Diminish Alzheimer’s Disease (CONCORD-AD): A Report of an International Research Collaboration Network.
- The global Alzheimer’s Association round robin study on plasma amyloid β methods.
- Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer’s disease.
- Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease.
- Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays.
- Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.
- Tau-related grey matter network breakdown across the Alzheimer’s disease continuum.
- Inter-modality assessment of medial temporal lobe atrophy in a non-demented population: application of a visual rating scale template across radiologists with varying clinical experience.
- Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease.
- Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers.
- Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
- Detecting amyloid positivity in early Alzheimer’s disease using combinations of plasma Aβ42/Aβ40 and p-tau.
- Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations.
- A multicentre validation study of the diagnostic value of plasma neurofilament light.
- Sex differences in off-target binding using tau positron emission tomography.
- Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects.
- The BIN1 rs744373 Alzheimer’s disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline.
- A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis.
- Health utility in preclinical and prodromal Alzheimer’s disease for establishing the value of new disease-modifying treatments-EQ-5D data from the Swedish BioFINDER study.
- Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau.
- Four distinct trajectories of tau deposition identified in Alzheimer’s disease.
- Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias.
- Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia.
- Accelerated inflammatory aging in Alzheimer’s disease and its relation to amyloid,
tau, and cognition.
- The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer’s
disease.
- Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer’s
disease.
- Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for
synaptic biomarkers.
- Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future
conversion to Alzheimer dementia in patients with mild cognitive impairment.
- A multisite analysis of the concordance between visual image interpretation and
quantitative analysis of [18F]flutemetamol amyloid PET images.
- Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer’s
disease.
- Biomarker testing in MCI patients-deciding who to test.
- Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts.
- Early stages of tau pathology and its associations with functional connectivity, atrophy and memory.
- Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease.
- Pre-analytical protocol for measuring Alzheimer’s disease biomarkers in fresh CSF.
- Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies.
- Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease.
- Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease.
- The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
- Derivation and utility of an Aβ-PET pathology accumulation index to estimate Aβ load.
- Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease
2020
- Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders
- Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia
- Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease
- Midlife Atherosclerosis and Development of Alzheimer or Vascular Dementia
- Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer’s disease
- Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease.
- Plasma Phospho-Tau Identifies Alzheimer’s Co-Pathology in Patients with Lewy Body Disease.
- Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias.
- Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer’s disease.
- Plasma NT1 Tau is a Specific and Early Marker of Alzheimer’s Disease.
- Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer’s disease.
- The impact of demographic, clinical, genetic, and imaging variables on tau PET status.
- Acute phase markers in CSF reveal inflammatory changes in Alzheimer’s disease that intersect with pathology, APOE ε4, sex and age.
- Image reconstruction methods affect software-aided assessment of pathologies of [18F]flutemetamol and [18F]FDG brain-PET examinations in patients with neurodegenerative diseases.
- Validation of a spatial normalization method using a principal component derived adaptive template for [18F]florbetaben PET.
- Medial temporal atrophy in preclinical dementia: Visual and automated assessment during six year follow-up.
- The effects of tau, amyloid and white matter lesions on mobility, dual tasking and balance in older people.
- Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease.
- Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults.
- CDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers.
- Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease
- The implications of different approaches to define AT(N) in Alzheimer disease.
- Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.
- Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
- Relationship between cortical iron and tau aggregation in Alzheimer’s disease.
- Medial temporal lobe connectivity and its associations with cognition in early Alzheimer’s disease.
- Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease.
- The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment.
- Towards unconstrained compartment modeling in white matter using diffusion-relaxation MRI with tensor-valued diffusion encoding.
- Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson’s disease.
- [18F]Flortaucipir Distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case.
- Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration.
- Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948.
- Apathy and anxiety are early markers of Alzheimer’s disease.
- Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease.
2019
2018
2017
2016
2015
2014
2013
2012